Search Results - "Thuss‐Patience, Peter"

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study by Thuss-Patience, Peter C, MD, Shah, Manish A, MD, Ohtsu, Atsushi, MD, Van Cutsem, Eric, Prof, Ajani, Jaffer A, Prof, Castro, Hugo, MD, Mansoor, Wasat, PhD, Chung, Hyun Cheol, Prof, Bodoky, Gyorgy, Prof, Shitara, Kohei, MD, Phillips, Gail D Lewis, MS, van der Horst, Tina, MSc, Harle-Yge, Marie-Laurence, MSc, Althaus, Betsy L, PharmD, Kang, Yoon-Koo, Prof

“…Summary Background Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is…”
Get full text

Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial by Fuchs, Charles S., Özgüroğlu, Mustafa, Bang, Yung-Jue, Di Bartolomeo, Maria, Mandala, Mario, Ryu, Min-Hee, Fornaro, Lorenzo, Olesinski, Tomasz, Caglevic, Christian, Chung, Hyun C., Muro, Kei, Van Cutsem, Eric, Elme, Anneli, Thuss-Patience, Peter, Chau, Ian, Ohtsu, Atsushi, Bhagia, Pooja, Wang, Anran, Shih, Chie-Schin, Shitara, Kohei

“…Background In the phase 3 KEYNOTE-061 study (cutoff: 10/26/2017), pembrolizumab did not significantly prolong OS vs paclitaxel as second-line (2L) therapy in…”
Get full text

Trastuzumab in combination with 5‐fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2‐positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group by Hofheinz, Ralf‐Dieter, Hegewisch‐Becker, Susanne, Kunzmann, Volker, Thuss‐Patience, Peter, Fuchs, Martin, Homann, Nils, Graeven, Ullrich, Schulte, Nadine, Merx, Kirsten, Pohl, Michael, Held, Swantje, Keller, Ralph, Tannapfel, Andrea, Al‐Batran, Salah‐Eddin

“…Perioperative chemotherapy with 5‐fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) is a mainstay in the treatment of esophagogastric adenocarcinomas…”
Get full text

Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapy by Masetti, Michael, Al‐Batran, Salah‐Eddin, Goetze, Thorsten O., Thuss‐Patience, Peter, Knorrenschild, Jorge Riera, Goekkurt, Eray, Folprecht, Gunnar, Ettrich, Thomas Jens, Lindig, Udo, Luley, Kim Barbara, Pink, Daniel, Dechow, Tobias, Sookthai, Disorn, Junge, Sabine, Loose, Maria, Pauligk, Claudia, Lorenzen, Sylvie

“…FOLFOX plus nivolumab represents a standard of care for first‐line therapy of advanced gastroesophageal cancer (aGEC) with positive PD‐L1 expression. The…”
Get full text

Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer by Shah, Manish A., Kang, Yoon-Koo, Thuss-Patience, Peter C., Ohtsu, Atsushi, Ajani, Jaffer A., Van Cutsem, Eric, Hoersch, Silke, Harle-Yge, Marie-Laurence, de Haas, Sanne Lysbet

“…Background Prespecified exploratory biomarker analyses of the phase II/III GATSBY study (NCT01641939) assessed whether patient subgroups experienced a survival…”
Get full text

The efficacy of treatment options for patients with gastric cancer and peritoneal metastasis by Rau, Beate, Brandl, Andreas, Thuss-Patience, Peter, Bergner, Fabian, Raue, Wieland, Arnold, Alexander, Horst, David, Pratschke, Johann, Biebl, Matthias

“…Background Patients with peritoneal metastases of gastric cancer have a poor prognosis and median survival of 7 months. This study compared treatment options…”
Get full text

Pazopanib with 5‐FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase‐II study—The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO‐STO‐0510 by Högner, Anica, Al‐Batran, Salah‐Eddin, Siveke, Jens T., Lorenz, Mario, Bartels, Prisca, Breithaupt, Kirstin, Malfertheiner, Peter, Homann, Nils, Stein, Alexander, Gläser, Dietrich, Tamm, Ingo, Hinke, Axel, Vogel, Arndt, Thuss‐Patience, Peter

“…VEGF inhibition in gastric cancer has a proven benefit in the second line setting. Pazopanib, an oral tyrosine kinase inhibitor, selectively inhibits VEGFR‐1,…”
Get full text

Association between oncologists' death anxiety and their end‐of‐life communication with advanced cancer patients by Harnischfeger, Nele, Rath, Hilke M., Alt‐Epping, Bernd, Brand, Hannah, Haller, Karl, Letsch, Anne, Rieder, Nicola, Thuss‐Patience, Peter, Bokemeyer, Carsten, Oechsle, Karin, Bergelt, Corinna

“…Objective Early and open communication of palliative care (PC) and end‐of‐life (EoL)‐related issues in advanced cancer care is not only recommended by…”
Get full text

Phase III randomized, double‐blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen (RADPAC) by Lorenzen, Sylvie, Knorrenschild, Jorge Riera, Pauligk, Claudia, Hegewisch‐Becker, Susanna, Seraphin, Jörg, Thuss‐Patience, Peter, Kopp, Hans‐Georg, Dechow, Tobias, Vogel, Arndt, Luley, Kim Barbara, Pink, Daniel, Stahl, Michael, Kullmann, Frank, Hebart, Holger, Siveke, Jens, Egger, Matthias, Homann, Nils, Probst, Stephan, Goetze, Thorsten Oliver, Al‐Batran, Salah‐Eddin

“…The RADPAC trial evaluated paclitaxel with everolimus in patients with advanced gastroesophageal cancer (GEC) who have progressed after therapy with a…”
Get full text

Anastomotic leak predicts diminished long-term survival after resection for gastric and esophageal cancer by Andreou, Andreas, MD, Biebl, Matthias, MD, Dadras, Mehran, MD, Struecker, Benjamin, MD, Sauer, Igor M., MD, Thuss-Patience, Peter C., MD, Chopra, Sascha, MD, Fikatas, Panagiotis, MD, Bahra, Marcus, MD, Seehofer, Daniel, MD, Pratschke, Johann, MD, Schmidt, Sven-Christian, MD

“…Background Previous studies have reported on the association between perioperative morbidity and diminished oncologic outcomes in patients undergoing resection…”
Get full text

German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer by Lordick, Florian, Al-Batran, Salah-Eddin, Arnold, Dirk, Borner, Markus, Bruns, Christiane J., Eisterer, Wolfgang, Faber, Gerhard, Gockel, Ines, Köberle, Dieter, Lorenzen, Sylvie, Möhler, Markus, Pritzkuleit, Ron, Stahl, Michael, Thuss-Patience, Peter, Wöll, Ewald, Zander, Thomas, Maschmeyer, Georg

“…The updated edition of the German, Austrian and Swiss Guidelines for Systemic Treatment of Gastric Cancer was completed in August 2023, incorporating new…”
Get full text

Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer by Smyth, Elizabeth, Thuss-Patience, Peter C

“…Recently some progress has been made in the palliative treatment of gastric cancer. It was shown that second-line chemotherapy and VEGF-R2-directed treatment…”
Get more information

Impact of Postoperative Chemotherapy in Patients with Gastric/Gastroesophageal Adenocarcinoma Treated with Perioperative Chemotherapy by Ballhausen, Alexej, Bartels, Prisca, Iacovella, Ines, Hoegner, Anica, Lorusso, Alessandro, Bichev, Dmitry, Daum, Severin, Thuss-Patience, Peter

“…Perioperative chemotherapy is the standard of care for patients undergoing curative resection for gastroesophageal adenocarcinoma. However, less than 50% of…”
Get full text

Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS) by Shitara, Kohei, Doi, Toshihiko, Hosaka, Hisashi, Thuss-Patience, Peter, Santoro, Armando, Longo, Federico, Ozyilkan, Ozgur, Cicin, Irfan, Park, David, Zaanan, Aziz, Pericay, Carles, Özgüroğlu, Mustafa, Alsina, Maria, Makris, Lukas, Benhadji, Karim A., Ilson, David H.

“…Background Trifluridine and tipiracil (FTD/TPI) demonstrated survival benefit vs placebo and manageable safety in previously treated patients with metastatic…”
Get full text

Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO) by Al-Batran, Salah-Eddin, Pauligk, Claudia, Homann, Nils, Schmalenberg, Harald, Kopp, Hans-Georg, Haag, Georg Martin, Luley Kim, Barbara, Schmiegel Wolff, H., Folprecht, Gunnar, Probst, Stephan, Prasnikar, Nicole, Thuss-Patience Peter, C., Trojan, Jorg, Goetze, Thorsten Oliver, Meiler, Johannes, Schuler Martin, H., Jäger, Elke, Hofheinz, Ralf-Dieter

Get full text

A FDG-PET radiomics signature detects esophageal squamous cell carcinoma patients who do not benefit from chemoradiation by Li, Yimin, Beck, Marcus, Päßler, Tom, Lili, Chen, Hua, Wu, Mai, Ha Dong, Amthauer, Holger, Biebl, Matthias, Thuss-Patience, Peter C., Berger, Jasmin, Stromberger, Carmen, Tinhofer, Ingeborg, Kruppa, Jochen, Budach, Volker, Hofheinz, Frank, Lin, Qin, Zschaeck, Sebastian

“…Detection of patients with esophageal squamous cell carcinoma (ESCC) who do not benefit from standard chemoradiation (CRT) is an important medical need…”
Get full text

Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study by Mansoor, Wasat, Arkenau, Hendrik-Tobias, Alsina, Maria, Shitara, Kohei, Thuss-Patience, Peter, Cuffe, Sinead, Dvorkin, Mikhail, Park, David, Ando, Takayuki, Van Den Eynde, Marc, Beretta, Giordano D., Zaniboni, Alberto, Doi, Toshihiko, Tabernero, Josep, Ilson, David H., Makris, Lukas, Benhadji, Karim A., Van Cutsem, Eric

“…Background Patients with advanced gastroesophageal junction cancer (GEJC) have poor survival outcomes, and GEJC-specific data from trials evaluating agents in…”
Get full text

Reply to F. Salani et al by Rau, Beate, Thuss-Patience, Peter C

Get full text

Immunotherapy in Squamous Cell Cancer of the Esophagus by Thuss-Patience, Peter, Stein, Alexander

“…Treatment of esophageal carcinoma has changed dramatically following several landmark trials, which have proven the benefit of immunotherapy. The selective…”
Get full text

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) by Thuss-Patience, Peter C, Kretzschmar, Albrecht, Bichev, Dmitry, Deist, Tillman, Hinke, Axel, Breithaupt, Kirstin, Dogan, Yasemin, Gebauer, Bernhard, Schumacher, Guido, Reichardt, Peter

“…Abstract Background The value of second-line therapy for metastatic gastric cancer is unclear. So far there are no randomised phase III data comparing…”
Get full text